Ms. Nisa LEUNG, JP
Nisa Leung is a Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading China venture capital firm which currently managing over USD 4.3 billion in assets.
She currently sits on the board of Gan & Lee Pharmaceutical, Zai Lab (NASDAQ: ZLAB), Venus MedTech (HKSE: 2500), Nurotron, dMed, CanSino Biologics (HKSE: 6185), New Horizon Bio, Berry Oncology, Insilico Medicine among others. Her other investments include Aeonmed Medical, Berry Genomics (SZSE: 000710), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Novast Pharmaceuticals, Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen, Cure Genetics, SinoCell Tech, Apollomics, Sino United, Schrödinger (NASDAQ: SDGR) and Jacobio among others.
Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019, named Top 3 Best Female Venture Capitalist in China by Forbes in 2018 and won Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017.
She is currently a visiting lecturer at Harvard Law School, a founding vice chair of PhIRDA Investment Committee, Committee member of Hong Kong Innovation and Technology Development and Re-Industrialization and member of Stanford Graduate School of Business Advisory Council. She also serves on the Board of Trustees of the Hotchkiss School and is a board member of the Hong Kong Palace Museum.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University.